SAN DIEGO, March 29 /PRNewswire/ -- Granite Financial has upgraded their recommendation from BUY to STRONG BUY on Boston Biomedica, Inc. (NASDAQ: BBII) -- $1.4063 -- in a recent four page updated report. The analyst is David N. Allen.
Granite Financial regards Boston Biomedica as a special situation. The
Company is developing a unique technology in Pressure Cycling Technology (PCT)
while building its diagnostics and related services. The diagnostics business
is the core company operation, and we are expecting considerable improved
results over the next two years. Management has executed several transactions
in recent months that enhance both the short-term and long-term outlook for
the company, as well as improving the financial position. We regard the stock
as undervalued, with limited downside and the potential to double over the
next year. We strongly recommend the stock for purchase.
SOURCE Granite Financial
CONTACT: David N. Allen, C.F.A. of Granite Financial Group, 858-509-8800
Web site: www.bbii.com
